Haemonetics enters amended credit agreement: $280M term loan, $420M revolver, maturity extended to June 2025

HAEMONETICS CORP

New $420M revolving credit facility (up from $350M) and $280M term loan to replace existing term loan.
Maturity extended by two years to June 15, 2025; quarterly amortization begins at 2.5% then 5%.
Interest: Adjusted Term SOFR plus 1.125%–1.750% credit spread based on leverage ratio.
Financial covenants: max leverage 3.50x (4.00x post-acquisition), min interest coverage 4.00x.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.